This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Oscar H. Del Brutto, MD

Arch Neurol. 1995;52(1):102-104.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE FIRST studies on specific drug therapy for neurocysticercosis (NCC) appeared more than one decade ago.^1-5 As usually occurs with pioneer work with many other drugs, such studies only included anecdotal case reports or small series of patients with different forms of the disease. Therefore, the efficacy of anticysticercal drugs was difficult to evaluate. A new age of knowledge on medical treatment for NCC began when Sotelo and coworkers^6,7 published the first controlled trials of praziquantel therapy in patients with parenchymal brain cysts. The authors used historical controls to demonstrate that viable cysticerci may live unchanged for several years within the brain parenchyma and that a course with praziquantel at daily doses of 50 mg per kilogram of body weight for 15 days destroys more than 60% of these cysts in less than 3 months. Using a similar design, several articles from different areas of the world further . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Neurology, Hospital Luis Vernaza, Guayaquil, Ecuador.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?